Comprehensive Genomic Profiling in Predictive Testing of Cancer.

Area of Science:

• Oncology
• Genomics
• Personalized Medicine

Background:

• Patient response to targeted therapies remains variable despite advances in personalized medicine.
• Current treatments often focus on a limited number of genes, potentially missing crucial genomic information.
• Comprehensive genomic profiling (CGP) offers a broader molecular characterization of tumors.

Purpose of the Study:

• To demonstrate the clinical utility of CGP in routine oncology practice.
• To showcase how CGP can guide personalized treatment decisions for advanced cancer patients.
• To highlight the potential of integrated DNA and RNA profiling for identifying actionable genomic alterations.

Main Methods:

• Utilized CGP by combining SOPHiA Solid Tumor Solution (42 genes, DNA) and SOPHiA RNAtarget Oncology Solution (45 genes and 17 gene fusions, RNA).
• Analyzed three patient cases with diverse advanced cancers.
• Identified somatic variants and gene fusions through next-generation sequencing and bioinformatics analysis.

Main Results:

• Actionable genomic alterations were identified in all three patient cases analyzed.
• CGP provided valuable molecular information essential for future patient management.
• The study successfully demonstrated the feasibility of integrating DNA and RNA profiling in clinical settings.

Conclusions:

• CGP is a valuable tool for enhancing clinical decision-making in advanced cancer care.
• Comprehensive molecular characterization through CGP can personalize innovative treatment strategies.
• This integrated genomic profiling approach holds significant potential to transform oncology practice and improve patient outcomes.